IlluminaILMN
ILMN
About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Employees: 8,970
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $139M | Put options by funds: $116M
0.36% more ownership
Funds ownership: 97.36% [Q4 2024] → 97.72% (+0.36%) [Q1 2025]
3% less repeat investments, than reductions
Existing positions increased: 261 | Existing positions reduced: 269
16% less funds holding
Funds holding: 841 [Q4 2024] → 709 (-132) [Q1 2025]
27% less funds holding in top 10
Funds holding in top 10: 15 [Q4 2024] → 11 (-4) [Q1 2025]
40% less capital invested
Capital invested by funds: $20.6B [Q4 2024] → $12.3B (-$8.33B) [Q1 2025]
58% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 209
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$80
26%
downside
Avg. target
$110
1%
upside
High target
$185
70%
upside
11 analyst ratings
4 positive
36%
5 neutral
45%
2 negative
18%
Baird Catherine Ramsey | 3%downside $105 | Neutral Maintained | 28 Jul 2025 |
Scotiabank Sung Ji Nam | 15%upside $125 | Sector Perform Downgraded | 11 Jul 2025 |
Citigroup Patrick Donnelly | 26%downside $80 | Sell Downgraded | 9 Jul 2025 |
Evercore ISI Group Vijay Kumar | 18%upside $128 | Outperform Maintained | 8 Jul 2025 |
Barclays Luke Sergott | 22%downside $85 | Underweight Maintained | 24 Jun 2025 |
Financial journalist opinion
Based on 6 articles about ILMN published over the past 30 days
Positive
Zacks Investment Research
5 days ago
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Negative
Benzinga
1 week ago
Illumina Stock: What Went Wrong And Why It's Best To Stay Away
Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.
Positive
Zacks Investment Research
2 weeks ago
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Positive
Seeking Alpha
2 weeks ago
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds
With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina. The global DNA sequencing market is expected to grow at a CAGR of 9% from 2024 and 2028, which is a positive aspect for Illumina. Illumina has reported higher gross profit margins than its peers, which reflects that its core business is profitable.
Neutral
PRNewsWire
2 weeks ago
Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025
SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Neutral
PRNewsWire
2 weeks ago
Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year
Illumina was also recognized as one of the Best Companies to Work For byU.S. News & World Report SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced two awards recognizing the company's leadership in sustainability practices and as an employer of choice. TIME named Illumina to its World's Most Sustainable Companies list for the second year in a row, and U.S. News & World Report named Illumina to its Best Companies to Work For list.
Positive
Zacks Investment Research
1 month ago
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
Positive
24/7 Wall Street
1 month ago
Cathie Wood Is Dumpster Diving Again With These 3 Stock Buys
Key Points in This Article: Cathie Wood's ARK Innovation ETF (ARKK) has seen a mixed performance over the past five years, reflecting her high-risk, high-reward focus on disruptive technologies to prosper over time.
Neutral
PRNewsWire
1 month ago
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024.
Positive
Zacks Investment Research
1 month ago
FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Charts implemented using Lightweight Charts™